MPS IVA (Morquio) Registry: The MARS Study

Morquio A Registry Study (MARS)

Protocol Description

The goals of this program are to characterize and describe the genetic disorder mucopolysaccharidosis type IV, A (MPS IVA), also known as Morquio syndrome, to better understand its progression and natural history. For participants taking Vimizim®, an enzyme replacement therapy, the study will also evaluate its long-term effectiveness. People with MPS IVA lack an enzyme known as GALNS that normally breaks down a certain type of sugar, leading to its accumulation in body tissues and causing physical problems such as: decreased growth; eye, throat, and ear problems; heart disease; lung problems; and bone and joint problems. Through this program, patient test results will be entered into a database along with other MPS IVA patients. Analysis of the collected information may lead to insights that will help physicians learn more about treating people with the condition.

Eligibility Criteria

Subject to certain exclusion criteria, the study is accepting patients of both genders and of all ages who have a confirmed diagnosis of MPS IVA.
Males and Females: All ages


Physicians must provide medical history information about their enrolled patients. Information from other tests required over time for disease management will be entered into the database. For participants who are also receiving enzyme replacement therapy, additional blood work may optionally be collected for analysis and entered into the study database.
Visits: Not applicable
Duration: 10 years

Status: Open to Enrollment

Source(s) of Support

BioMarin Pharmaceutical

Primary Investigator

Gerard Vockley, MD, PhD

Contact Information

For more information about the study or enrollment, please contact:
Nadene Henderson, MS, LCGC